Mitigation of indomethacin-induced gastric mucosal lesions by a potent specific type V phosphodiesterase inhibitor

• Published in: World journal of gastroenterology : WJG 2009-10, Vol.15 (40), p.5091-5096
• Main Author: Kemal Karakaya Volkan Hanci Sibel Bektas Murat Can Hamdi B Ucan Ali Ugur Emre Oge Tascllar, Isll Ozkocak Turan Mustafa Comert Oktay Irkorucu Guldeniz Karadeniz Cakmak
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - therapeutic use; Brief; Cyclooxygenase Inhibitors - adverse effects; Famotidine - therapeutic use; Female; Gastric Mucosa - drug effects; Humans; Imidazoles - therapeutic use; Indomethacin - adverse effects; Malondialdehyde - metabolism; METHODS; Nitric Oxide - chemistry; Nitric Oxide - metabolism; Oxidative Stress; Phosphodiesterase Inhibitors - therapeutic use; Piperazines - therapeutic use; Rats; Rats, Wistar; Sulfones - therapeutic use; Triazines - therapeutic use; Vardenafil Dihydrochloride; 胃疾病; 胃黏膜
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.15.5091

AIM： To investigate the gastroprotective effect of vardenafil against indomethacin-induced gastric damage. METHODS： Forty-eight female Wistar albino rats were randomly divided into 6 groups. Group 1 received saline only. Group 2 （indomethacin） received indomethacin. Rats in group 3 and 4 were pretreated with different doses of famotidine, Group 5 and 6 were pretreated with different doses of vardenafil. Rats in groups 3 to 6 received 25 mg/kg indomethacin 30 min after pretreatment. The animals were sacrificed 6 h later and their stomachs were opened. Gastric lesions were counted and measured. The stomach of each animal was divided in two parts for histopathological examinations and nitric oxide （NO） and malondialdehyde （MDA） assays, respectively.RESULTS： There were no gastric mucosal lesion in the saline group but all rats in the indomethacin group had gastric mucosal ulcerations （ulcer count; 6.25 ± 3.49, and mean ulcer area; 21.00 ± 12.35）. Ulcer counts were diminished with famotidine 5 mg/kg （4.12 ± 2.47, P 〉 0.05）, 20 mg/kg （2.37 ± 4.43, P 〈 0.05）, vardenafil 2 mg/kg （4.37 ± 3.06）, and vardenafil 10 mgkg （1.25 ± 1.38, P 〈 0.05） compared to the indomethacin group. Gastric mucosal lesion areas were diminished with famotidine 5 mg/kg （8.62 ± 2.97, P 〈 0.001）, famotidine 20 mg/kg （0.94 ± 2.06, P 〈 0.001）, vardenafil 2 mg/kg （6.62 ± 5.87, P 〈 0.001）, and vardenafil 10 mg/kg （0.75 ± 0.88, P 〈 0.001） compared to the indomethacin group. MDA levels were significantly higher in indomethacin group （28.48 ± 14.51）, compared to the famotidine 5 mg/kg （6,21 ± 1.88, P 〈 0.05）, famotidine 20 mg/kg （5.88 ± 1.60. P 〈 0.05）, vardenafil 2 mg/kg （15.87 ± 3.93, P 〈 0.05）, and vardenafil 10 mg/kg （10.97 ± 4.50, P 〈 0.05）. NO concentration in gastric tissues of the famotidine groups （were significantly increased （P 〈 0.05）, but the NO increases in the vardenafil groups were not statistically significant. Histopathology revealed diminished gastric damage for pretreatment groups compared to the indomethacin group （P 〈 0.05）.CONCLUSION： Vardenafil affords a significant dosedependent protection against indomethacin induced gastric mucosal lesions in rats.